FDA approves Illumigene HSV 1&2 diagnostics for herpes simplex- Meridian Bioscience
Meridian Bioscience has received FDA clearance for two new molecular assays for the detection of herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2), to be run on its Illumigene molecular platform. The Illumigene HSV 1&2 assays, launched in May this year in Europe, are now available in the US – they are the eighth and ninth assays added to the illumigene molecular menu now that includes C. difficile, Group A Streptococcus, Group B Streptococcus, Mycoplasma, Pertussis, Chlamydia and Gonorrhea.
Illumigene HSV 1&2 assays utilize loop-mediated isothermal DNA amplification (LAMP) technology for the qualitative detection and differentiation of HSV-1 and HSV-2 in cutaneous and mucocutaneous specimens. The test procedure is simple, sensitive and provides results in less than one hour.
Related news and insights
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the Phase IIIb COSMOS clinical trial showing that treatment with Tremfya (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR)
Pfizer Inc. announced the first detailed results from the Phase II PHAROS study, which is evaluating the efficacy and safety of Braftovi (encorafenib) given in combination with Mektovi(binimetinib) to patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
Legend Biotech Corp announced that results from the Phase III CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel (ciltacabtagene autoleucel) reduced the risk of disease progression or death by 74 percent compared to standard of care regimens in adult patients with multiple myeloma who have received one to three prior lines of therapy and are refractory to lenalidomide (Hazard ratio [HR]=0.26 (95% CI, 0.18–0.38); P-value [P] <0.0001)